Developing a new ointment to treat skin infections caused by drug-resistant bacteria
Official title: A broad-spectrum antimicrobial ointment containing Bi2O3 NPs for skin and soft tissue infections by multidrug-resistant bacteria
Funded at Kent State University · NIH-10766245 · Data updated 2026-11-12
This study is testing a new ointment made with tiny particles to help treat stubborn skin infections caused by tough bacteria that don't respond well to regular antibiotics, giving patients a better option for healing.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kent State University NIH-funded |
| Lab location | 1 site (Kent, United States) |
| Project start | January 19, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $77,566 |
| NIH project number | 5R03AI175990-02 |
| Project ID | NIH-10766245 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from skin and soft tissue infections caused by multidrug-resistant bacteria.
✕Less likely to help
Patients with infections caused by non-resistant bacteria or those who do not have skin and soft tissue infections may not benefit from this research.
What this research studies
This research focuses on creating a new broad-spectrum antimicrobial ointment that utilizes bismuth oxide nanoparticles to effectively treat skin and soft tissue infections (SSTIs) caused by multidrug-resistant bacteria. The approach aims to address the growing issue of antibiotic resistance, particularly with superbugs like MRSA and Pseudomonas aeruginosa, which have made traditional treatments less effective. By developing this innovative ointment, the research seeks to provide a viable alternative to current topical antibiotics, which are becoming increasingly limited. Patients may benefit from a more effective treatment option that could reduce the reliance on systemic antibiotics and combat the rise of drug-resistant infections.
Why it matters
Potential benefit: If successful, this research could provide patients with a new, effective treatment option for skin infections that are currently difficult to manage due to antibiotic resistance.
How similar studies have gone: While the approach of using nanoparticles in antimicrobial treatments is gaining interest, this specific formulation and its application for SSTIs is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Kent State University
Kent, United States Active
Researchers
- Principal investigator: Huang, Songping D — Kent State University
- Study coordinator: Huang, Songping D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.